| 02/01 | BeiGene to Present at Upcoming Investor Conferences | BU |
| 01/24 | Morgan Stanley Adjusts Price Target on BeiGene to $325 From $295, Maintains Overweight .. | MT |
| 01/23 | Beigene : Announces Expansion of Coverage on China's National Reimbursement Drug List - Fo.. | PU |
| 01/20 | Asian Equities Rally in Friday Trading as ADRs Set to Close Week 2% Higher | MT |
| 01/20 | Guggenheim Raises Price Target on BeiGene to $350 From $290, Maintains Buy Rating | MT |
| 01/20 | SVB Securities Adjusts Price Target on BeiGene to $300 From $236, Maintains Outperform .. | MT |
| 01/20 | Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas.. | AQ |
| 01/20 | BRUKINSA Receives Marketing Authorization for Chronic Lymphocytic Leukemia and Marginal.. | AQ |
| 01/19 | US FDA Approves BeiGene's Lymphocytic Leukemia Treatment | MT |
| 01/19 | BeiGene's Brukinsa Secures US FDA Approval for Chronic Lymphocytic Leukemia | MT |
| 01/19 | BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia | BU |
| 01/19 | BeiGene Announces BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia | CI |
| 01/19 | BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List | AQ |
| 01/19 | BeiGene Says Brukinsa Gets UK Marketing Authorization for Chronic Lymphocytic Leukemia,.. | MT |
| 01/19 | BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leuke.. | BU |
| 01/19 | Brukinsa (Zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukem.. | CI |
| 01/19 | Four New Indications for BeiGene's Tislelizumab Included in China's Expanded National R.. | MT |
| 01/18 | BeiGene Says China National Reimbursement Drug List Expanded Coverage of its Drugs | MT |
| 01/18 | BeiGene Announces Expansion of Coverage on China's National Reimbursement Drug List | BU |
| 01/18 | BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug Lis.. | CI |
| 01/17 | Insider Sell: Beigene | MT |
| 01/17 | BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO.. | BU |
| 01/17 | Leap Therapeutics Acquires Flame Biosciences | AQ |
| 01/12 | Insider Sell: Beigene | MT |
| 01/11 | Insider Sell: Beigene | MT |
| 01/09 | Transcript : BeiGene, Ltd. Presents at 41st Annual J.P. Morgan Healthcare Con.. | CI |
| 01/05 | Beigene : Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor T.. | PU |
| 01/05 | BeiGene, Ltd. Announces Center for Drug Evaluation of the China National Medical Produc.. | CI |
| 01/04 | BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference | BU |
| 01/01 | Chinese Regulator Accepts BeiGene's Biologics License Application for Hepatocellular Ca.. | MT |
| 2022 | BeiGene Says Chinese Regulator Accepts Application for Tislelizumab to Treat Liver Canc.. | MT |
| 2022 | BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor .. | BU |
| 2022 | BeiGene Announces Acceptance of 12th Regulatory Submission in China for PD-1 Inhibitor .. | CI |
| 2022 | Asian Equities Follow US Market Sell-Off, Move Sharply Lower Thursday | MT |
| 2022 | Jazz Pharmaceuticals And Zymeworks Announce Jazz Has Confirmed Opt-In And Advances Part.. | AQ |
| 2022 | BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange Composite.. | CI |
| 2022 | BeiGene, Ltd.(SHSE:688235) added to Shanghai Stock Exchange A Share I.. | CI |
| 2022 | Immix Biopharma Doses 16th Patient in Phase 1b/2a IMX-110 Monotherapy Trial | MT |
| 2022 | Zymeworks Announces Positive Topline Data in The Pivotal HERIZON-BTC-01 Trial Of Zanida.. | AQ |
| 2022 | Indian Morning Briefing: Asian Markets Track Wall Street Lower | DJ |
| 2022 | Certain Restricted Share Units of BeiGene, Ltd. are subject to a Lock-Up Agreement Endi.. | CI |
| 2022 | Certain Options of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-20.. | CI |
| 2022 | Certain A Shares of BeiGene, Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2.. | CI |
| 2022 | BeiGene's BRUKINSA Demonstrated Superior Progression-Free Survival Over IMBRUVICA in Ch.. | AQ |
| 2022 | BeiGene Lymphocytic Leukemia Treatment Shows Efficacy in Phase 3 Trial
| MT |
| 2022 | Transcript : BeiGene, Ltd. - Special Call | CI |
| 2022 | BeiGene Says Final Phase 3 Study Data Show Brukinsa More Effective Than Imbruvica in Ch.. | MT |
| 2022 | BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Ove.. | BU |
| 2022 | Beigene, Ltd.'S Brukinsa Demonstrated Superior Progression-Free Survival over Imbruvica.. | CI |
| 2022 | Asian Equities Drop Sharply as COVID Infections Surge in China | MT |
| 2022 | Zymeworks Inc - New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cance.. | AQ |
| 2022 | BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey .. | AQ |
| 2022 | SVB Securities Adjusts BeiGene Price Target to $236 From $210, Maintains Outperform Rat.. | MT |
| 2022 | Transcript : BeiGene, Ltd. - Special Call | CI |
| 2022 | BeiGene Calls for Greater Integration of Mental Health in Cancer Care After New Survey .. | BU |
| 2022 | BeiGene, Phanes Therapeutics to Evaluate PT199-Tislelizumab Combo in Solid Tumor Trial | MT |
| 2022 | Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 .. | PR |
| 2022 | Asian Equities Decline Despite Reports China Will Further Ease COVID Restrictions | MT |
| 2022 | BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B.. | AQ |
| 2022 | BeiGene to Present Final PFS Results from ALPINE Trial Demonstrating Superior PFS for B.. | BU |
| 2022 | Beigene to Present Final Pfs Results from Alpine Trial Demonstrating Superior Pfs for B.. | CI |
| 2022 | Beigene, Ltd. Announces Change of Co-Chair of Scientific Advisory Committee | CI |
| 2022 | BeiGene Receives European Commission Approval for BRUKINSA for the Treatment of Adults .. | AQ |
| 2022 | European Commission Approves BeiGene's Chronic Lymphocytic Leukemia Treatment; Shares S.. | MT |
| 2022 | BeiGene's Brukinsa Drug Wins EU Nod For Chronic Lymphocytic Leukemia | MT |
| 2022 | Insider Sell: Beigene | MT |
| 2022 | Insider Sell: Beigene | MT |
| 2022 | Sector Update: Health Care Stocks Decline Premarket Thursday | MT |
| 2022 | BeiGene Says European Commission Approves Brukinsa as Treatment for Chronic Lymphocytic.. | MT |
| 2022 | BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Trea.. | BU |
| 2022 | BeiGene Receives European Commission Approval for Brukinsa® (Zanubrutinib) for the Trea.. | CI |
| 2022 | BeiGene Launches Talk About It Program to Elevate the Importance of Addressing Mental H.. | BU |
| 2022 | BeiGene's Brukinsa Secures Brazilian Approvals for Certain Cancers; Shares Rise | MT |
| 2022 | SVB Securities Adjusts Price Target on BeiGene to $210 From $200, Maintains Outperform .. | MT |
| 2022 | Nomura Adjusts BeiGene Price Target to $281.78 From $286.31, Maintains Buy Rating | MT |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
